Logo image of NTRA

NATERA INC (NTRA) Stock Fundamental Analysis

USA - NASDAQ:NTRA - US6323071042 - Common Stock

178.01 USD
-2.53 (-1.4%)
Last: 10/17/2025, 9:35:08 AM
Fundamental Rating

4

Taking everything into account, NTRA scores 4 out of 10 in our fundamental rating. NTRA was compared to 536 industry peers in the Biotechnology industry. NTRA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, NTRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

NTRA had negative earnings in the past year.
In the past year NTRA had a positive cash flow from operations.
NTRA had negative earnings in each of the past 5 years.
In the past 5 years NTRA reported 4 times negative operating cash flow.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

NTRA has a Return On Assets of -14.41%. This is amongst the best in the industry. NTRA outperforms 82.46% of its industry peers.
The Return On Equity of NTRA (-20.32%) is better than 84.33% of its industry peers.
Industry RankSector Rank
ROA -14.41%
ROE -20.32%
ROIC N/A
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

With a decent Gross Margin value of 62.86%, NTRA is doing good in the industry, outperforming 79.66% of the companies in the same industry.
In the last couple of years the Gross Margin of NTRA has grown nicely.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

7

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTRA has been increased compared to 1 year ago.
NTRA has more shares outstanding than it did 5 years ago.
NTRA has a better debt/assets ratio than last year.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 28.20 indicates that NTRA is not in any danger for bankruptcy at the moment.
NTRA has a Altman-Z score of 28.20. This is amongst the best in the industry. NTRA outperforms 92.91% of its industry peers.
NTRA has a debt to FCF ratio of 0.77. This is a very positive value and a sign of high solvency as it would only need 0.77 years to pay back of all of its debts.
NTRA has a Debt to FCF ratio of 0.77. This is amongst the best in the industry. NTRA outperforms 95.34% of its industry peers.
NTRA has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.06, NTRA is not doing good in the industry: 61.75% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for NTRA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.77
Altman-Z 28.2
ROIC/WACCN/A
WACC9.37%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

NTRA has a Current Ratio of 3.72. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.72, NTRA perfoms like the industry average, outperforming 43.28% of the companies in the same industry.
A Quick Ratio of 3.58 indicates that NTRA has no problem at all paying its short term obligations.
The Quick ratio of NTRA (3.58) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.58
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.04%, which is quite impressive.
The Revenue has grown by 44.38% in the past year. This is a very strong growth!
NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.20% yearly.
EPS 1Y (TTM)22.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.67%
Revenue 1Y (TTM)44.38%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%32.24%

3.2 Future

The Earnings Per Share is expected to grow by 27.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.69% on average over the next years. This is quite good.
EPS Next Y-29.03%
EPS Next 2Y10.2%
EPS Next 3Y32.38%
EPS Next 5Y27.58%
Revenue Next Year24.79%
Revenue Next 2Y20.06%
Revenue Next 3Y19.86%
Revenue Next 5Y16.69%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 91.04% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 233.67
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as NTRA's earnings are expected to grow with 32.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.2%
EPS Next 3Y32.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATERA INC

NASDAQ:NTRA (10/17/2025, 9:35:08 AM)

178.01

-2.53 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners93.57%
Inst Owner Change0.08%
Ins Owners3.13%
Ins Owner Change-1.63%
Market Cap24.43B
Analysts84.29
Price Target197.96 (11.21%)
Short Float %2.87%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.64%
Min EPS beat(2)-17.78%
Max EPS beat(2)23.06%
EPS beat(4)2
Avg EPS beat(4)14.54%
Min EPS beat(4)-17.78%
Max EPS beat(4)55.66%
EPS beat(8)6
Avg EPS beat(8)19.24%
EPS beat(12)9
Avg EPS beat(12)15.23%
EPS beat(16)11
Avg EPS beat(16)9.5%
Revenue beat(2)2
Avg Revenue beat(2)11.38%
Min Revenue beat(2)10.25%
Max Revenue beat(2)12.51%
Revenue beat(4)4
Avg Revenue beat(4)12.74%
Min Revenue beat(4)8.92%
Max Revenue beat(4)19.28%
Revenue beat(8)8
Avg Revenue beat(8)11.42%
Revenue beat(12)10
Avg Revenue beat(12)8.34%
Revenue beat(16)14
Avg Revenue beat(16)6.87%
PT rev (1m)-1.93%
PT rev (3m)-3.09%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)32.91%
EPS NY rev (1m)-0.72%
EPS NY rev (3m)12%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)2.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.44
P/FCF 233.67
P/OCF 130.86
P/B 19.61
P/tB 19.61
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)0.76
FCFY0.43%
OCF(TTM)1.36
OCFY0.76%
SpS14.31
BVpS9.08
TBVpS9.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.41%
ROE -20.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.86%
FCFM 5.32%
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score6
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.77
Debt/EBITDA N/A
Cap/Depr 234.12%
Cap/Sales 4.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.72
Quick Ratio 3.58
Altman-Z 28.2
F-Score6
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.67%
EPS Next Y-29.03%
EPS Next 2Y10.2%
EPS Next 3Y32.38%
EPS Next 5Y27.58%
Revenue 1Y (TTM)44.38%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%32.24%
Revenue Next Year24.79%
Revenue Next 2Y20.06%
Revenue Next 3Y19.86%
Revenue Next 5Y16.69%
EBIT growth 1Y6.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.74%
EBIT Next 3Y44.52%
EBIT Next 5Y31.12%
FCF growth 1Y127%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.49%
OCF growth 3YN/A
OCF growth 5YN/A